Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis

ConclusionsAll actual PFP users could safely and effectively administer ADL-PF by PFP at each visit, and nearly all participants who completed the sub-study elected to continue study treatment using PFP injections.Trial registrationClinicalTrials.gov identifier: NCT02480153; EudraCT number: 2014-000352-29.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research